Innate Pharma announces data presentations on monalizumab at the European Society for Medical Oncology annual meeting 2018
Innate Pharma reports IPH4102 results in advanced Cutaneous T Cell Lymphoma (CTCL)
Innate Pharma reports first half 2018 financial results and business update
Innate pharma announces enrollment of first patient in the Phase I study of IPH5401 in combination with durvalumab (Imfinzi®) in solid tumors
Innate Pharma announces data presentations at upcoming scientific meetings
Innate pharma announces a change to its 2018 financial calendar
Clinical data from ongoing Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) in colorectal cancer patients presented at 2018 ASCO annual meeting
Outcome of Annual General Meeting of May 29, 2018
Preliminary data from a Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) show anti-tumor activity in colorectal cancer patients
First quarter 2018 report
